STOCK TITAN
  1. Home
  2. News
  3. BIIB

Biogen Inc - BIIB STOCK NEWS

IMPACT
SENTIMENT
BIIB : Nasdaq
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
fda approval
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Completes Acquisition of Reata Pharmaceuticals
acquisition
IMPACT
SENTIMENT
BIIB : Nasdaq
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
IMPACT
SENTIMENT
BIIB : Nasdaq
Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Appoints Jane Grogan as Head of Research
management
IMPACT
SENTIMENT
BIIB : Nasdaq
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
clinical trial fda approval
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen to Acquire Reata Pharmaceuticals
acquisition
IMPACT
SENTIMENT
BIIB : Nasdaq
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
IMPACT
SENTIMENT
BIIB : Nasdaq
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
IMPACT
SENTIMENT
BIIB : Nasdaq
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Stock BIIB logo
Biogen Inc
Nasdaq:BIIB

BIIB Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link

About BIIB

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili